Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers

BACKGROUND AND AIMS: Biliary tract cancers are rare, heterogeneous cancers with poor prognoses. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII (a TGF-β “trap”) fused to a human IgG1 monoclonal antibody blocking programmed death ligand 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Changhoon, Javle, Milind M., Verdaguer Mata, Helena, de Braud, Filippo, Trojan, Jörg, Raoul, Jean-Luc, Kim, Jin Won, Ueno, Makoto, Lee, Choong-kun, Hijioka, Susumu, Cubillo, Antonio, Furuse, Junji, Azad, Nilofer, Sato, Masashi, Vugmeyster, Yulia, Machl, Andreas, Bajars, Marcis, Bridgewater, John, Oh, Do-Youn, Borad, Mitesh J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles: Liver Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442127/
https://www.ncbi.nlm.nih.gov/pubmed/36999533
http://dx.doi.org/10.1097/HEP.0000000000000365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442127/
https://www.ncbi.nlm.nih.gov/pubmed/36999533
http://dx.doi.org/10.1097/HEP.0000000000000365

Ejemplares similares